COMPANY

Intima Bioscience

HQ: New York, NY (US office) source · intimabioscience.com ↗ · Mid-Atlantic

Location: New York, NY (US office) · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Gastrointestinal Cancer Non-Small-Cell Lung Carcinoma Metastatic Non Small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer Squamous Cell Lung Cancer Adenocarcinoma of Lung Large Cell Lung Cancer Gastrointestinal Epithelial Cancer Gastrointestinal Neoplasms Cancer of Gastrointestinal Tract Colo-rectal Cancer Pancreatic Cancer Gall Bladder Cancer Colon Cancer Esophageal Cancer Stomach Cancer

2Trials (company is sponsor)

Timeline

2023-02 Trial start Phase 1/Phase 2: CISH Inactivated TILs in the Treatment of NSCLC source ↗
May 15, 2020 Trial start Phase 1/Phase 2: A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISP source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT05566223	CISH Inactivated TILs in the Treatment of NSCLC	Phase 1/Phase 2	Withdrawn	2023-02	2025-11 (estimated)
NCT04426669	A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering	Phase 1/Phase 2	Completed	May 15, 2020	May 28, 2025 (actual)